Patents Assigned to University of Maryland, Baltimore
  • Publication number: 20200155643
    Abstract: Engineered anthrax protective antigen (PrAg) proteins are provided wherein the native furin activation site is replaced by the activation site of a membrane-anchored serine protease. These engineered PrAg proteins retain the ability to bind to cell surface PrAg receptors and be proteolytically activated. The proteins also retain the ability to form membrane pores. These engineered PrAg proteins can be used in methods of inducing pore formation in a cell, methods of inducing translocation of a selected compound or co-factor into a cell, and methods of treating disease, such as cancer, in a subject.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: University of Maryland, Baltimore
    Inventors: Toni ANTALIS, Erik MARTIN
  • Publication number: 20200155132
    Abstract: The present invention provides transseptal puncture devices configured to access structures on the left side of the heart from the right side of the heart without requiring open-heart surgery. The devices have adjustable stiffness to enter the vasculature in a flexible, atraumatic fashion, then become rigid once in place to provide a stable platform for penetration of the fossa ovalis. The devices are further configured to controllably and stably extend a needle to puncture the FO. The devices include an indwelling blunt stylus that can extend perpendicularly from the device to increase the accuracy of placement near the fossa ovalis.
    Type: Application
    Filed: September 20, 2019
    Publication date: May 21, 2020
    Applicants: University of Maryland, Baltimore, University of Maryland Medical System, LLC
    Inventors: James S. GAMMIE, Rachael QUINN, Chetan PASRIJA
  • Publication number: 20200150112
    Abstract: Seroprotection analysis systems, kits, and techniques are described for testing oral fluid for the presence of protective levels of antibodies of interest. In one aspect, the presence of protective levels of target antibodies indicates a test subject has achieved a target seroprotection level, such as but not limited to a target seroprotection level following vaccination. A collection kit can include a swab that enables collection of oral fluid containing antibodies from both dentulous and edentulous individuals, a container that can be pre-filled with an extraction solution, and a nozzle that can be coupled to the container to form a fluid-tight device. A user can use the nozzle to seal the swab in the container and to compress the swab within the container.
    Type: Application
    Filed: December 23, 2019
    Publication date: May 14, 2020
    Applicants: Becton, Dickinson and Company, University of Maryland, Baltimore
    Inventors: Michael D. Fiechtner, Francis R. Go, Myron Levine, Scott Castanon
  • Patent number: 10646331
    Abstract: Disclosed herein is a customized ossicular prosthesis suitable for treatment of conductive hearing loss due to ossicular chain defects, and a method and system for manufacturing the same. Medical imaging equipment can detect specifically designated landmarks in normal human middle ear ossicles, including significant anatomic differences in those structures. Those anatomic features are used to generate a customized ossicular prosthesis specifically configured for a particular patient's anatomy using 3D printing techniques and devices.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 12, 2020
    Assignee: University of Maryland, Baltimore
    Inventors: Jeffrey Hirsch, David J. Eisenman
  • Patent number: 10646490
    Abstract: The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds and prodrugs thereof that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Katherine L. Radtke
  • Patent number: 10639024
    Abstract: Apparatus and methods for performing a non-invasive procedure to repair a cardiac valve are described herein. In some embodiments, apparatus and methods are described herein for repairing a mitral valve using an edge-to-edge repair to secure the mitral valve leaflets. Implant securing devices are also described that can be used during a procedure to repair a mitral valve. In some embodiments, an implant securing device includes an outer member and an inner member movably disposed within the outer member. The inner member can be used to hold or secure a suture extending from an implant deployed on an atrial side of a leaflet of a mitral valve, and the outer member can be used to push or move a half hitch knot toward a ventricular side of the leaflet, which can be used to secure the implant in the desired position.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 5, 2020
    Assignees: University of Maryland, Baltimore, Harpoon Medical, Inc.
    Inventors: James Gammie, Peter Wilson, Peter Boyd, William Niland
  • Publication number: 20200129470
    Abstract: Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and one or more additional therapeutic agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, ART-631, and ART-838. The one or more additional therapeutic agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Curt I. Civin, Blake S. Moses
  • Publication number: 20200129305
    Abstract: A Cloward-style cage device for anterior cervical fusion and fixation includes a body and a lateral stabilizer. The device uses the historical Cloward-style approach, and, as such, decompresses the interbody disc. The device can be used with a cylindrical drill bit to drill through the interbody disc to remove a portion of the interbody endplates to decompress a remaining portion of the interbody disc. The lateral portions of the endplates are generally preserved. The device has a cylindrical body formed of a mesh-like material, with lateral stabilizers.
    Type: Application
    Filed: April 24, 2018
    Publication date: April 30, 2020
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventor: Charles SANSUR
  • Patent number: 10632305
    Abstract: Studies of the pathogenic mechanisms underlying human myopathies and muscular dystrophies often require animal models, but models of some human diseases are not yet available. The present invention provides methods to promote the engraftment and development of myogenic cells from individuals with such diseases into mature muscle tissue in mice to treat muscle diseases, muscle injury and reduced muscle function. Immortalized human myogenic precursor cells (hMPCs) form mature human myofibers following implantation into the hindlimbs of immunodeficient mice. The engraftment of the cells and their development into mature muscle myofibers is promoted by intermittent neuromuscular electrical stimulation (iNMES) of the peroneal nerve of the engrafted limb. The human myofibers that form are innervated, their contractile apparatus is fully differentiated, and they are comprised of human myonuclei, with minimal contamination by murine myonuclei.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: April 28, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Robert J. Bloch, Andrea O'Neill, Joseph A. Roche, Paraskevi Sakellariou
  • Publication number: 20200121705
    Abstract: The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R1 and R2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R3 may be OH or a mono-, di- or poly-saccharide, R4, R5, R6 and R7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R8, R9, R10 and R11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.
    Type: Application
    Filed: October 4, 2017
    Publication date: April 23, 2020
    Applicant: University of Maryland, Baltimore
    Inventors: Robert K. Ernst, Erin M. Harberts, Alison J. Scott
  • Patent number: 10617685
    Abstract: Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), Kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 14, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Vincent C. O. Njar, Puranik Purushottamachar
  • Patent number: 10583313
    Abstract: The present disclosure relates to a new scan technique for particle radiation therapy that may be used for cancer treatment. One embodiment relates to a method of mitigating interplay effect in particle radiation therapy in a moving target including a period of movement, where the particle radiation therapy defines a planned dose in each spot of each layer of the moving target. The method comprising dividing the planned dose in each spot into a number of spot repaintings; and generating a scan pattern for each layer by defining a beam-on time at each spot for each spot repainting, and calculating a wait time between consecutive beam-on times to distribute the spot repaintings for each spot of a respective layer are distributed over a duration of an integer number of periods of movement.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 10, 2020
    Assignees: Varian Medical Systems Particle Therapy GmbH, University of Maryland, Baltimore
    Inventors: Per Rugaard Poulsen, John Eley, Ulrich Langner, Katja Langen
  • Publication number: 20200071392
    Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).
    Type: Application
    Filed: August 15, 2017
    Publication date: March 5, 2020
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Li MAO, Hening REN
  • Patent number: 10568929
    Abstract: Engineered anthrax protective antigen (PrAg) proteins are provided wherein the native furin activation site is replaced by the activation site of a membrane-anchored serine protease. These engineered PrAg proteins retain the ability to bind to cell surface PrAg receptors and be proteolytically activated. The proteins also retain the ability to form membrane pores. These engineered PrAg proteins can be used in methods of inducing pore formation in a cell, methods of inducing translocation of a selected compound or co-factor into a cell, and methods of treating disease, such as cancer, in a subject.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Toni Antalis, Erik Martin
  • Patent number: 10571465
    Abstract: Techniques for metal enhanced fluorescence include determining a calibration curve that relates concentration of a particular analyte to at least one of intensity or lifetime of fluorescent emissions at a plasmonic substrate in response to incident light, for a plurality of known concentrations of the particular analyte mixed with a reagent. The reagent comprises a detection molecule. A concentration of the particular analyte in a vicinity of a cell in a sample is determined directly from the calibration curve and measurements, in response to the incident light, of at least one of intensity or lifetime of fluorescent emissions at the plasmonic substrate in contact with the cell and reagent.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: February 25, 2020
    Assignee: The University of Maryland, Baltimore
    Inventors: Henryk Szmacinski, Joseph R. Lakowicz
  • Publication number: 20200056153
    Abstract: The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 20, 2020
    Applicants: GPB SCIENTIFIC, LLC, UNIVERSITY OF MARYLAND, BALTIMORE, THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Anthony WARD, Roberto CAMPOS-GONZALEZ, Alison SKELLEY, Khushroo GANDHI, Curt CIVIN, James C. STURM, Michael GRISHAM
  • Patent number: 10561658
    Abstract: The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 18, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: Katherine L. Radtke, Kartik Temburnikar
  • Patent number: 10561712
    Abstract: The beta 2 subunit of mouse hemoglobin (HBB2) has been identified as soluble factor from mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma lung micrometastases. The beta subunit of human hemoglobin (HBB) has been found to have similar activity. Methods of using these proteins and fragments thereof in the treatment of cancer and inhibition of metastasis are provided, along with methods of screening a subject for micrometastases by detecting HBB in a biological sample.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: February 18, 2020
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Wuyuan Lu, Issac Witz, Shelly Maman
  • Patent number: 10556124
    Abstract: A method and apparatus is presented for optimizing a treatment plan for irradiation therapy. The method includes defining a single objective function based on a plurality of objective functions that are each associated with a plurality of tissue types within a subject, upper and lower bounds for each objective function and a plurality of apertures. The method also includes determining a radiation dose delivered to voxels of each tissue type based on minimizing the single objective function based on the plurality of apertures with initial values at each angle. The method also includes delivering a beam of radiation with controlled intensity and beam cross-sectional shape at each angle based on the plurality of apertures.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 11, 2020
    Assignee: University of Maryland, Baltimore
    Inventors: Hao H. Zhang, Gokhan Kirlik, Warren D. D'Souza
  • Patent number: 10556931
    Abstract: The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and O12. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 11, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Raphael Simon, Alan Cross, Sharon Tennant